Astellas Pharma Inc (4503.T)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2018||Chairman of the Board, Chairman of the Board of Directors, Representative Director|
|57||2018||President, Chief Executive Officer, Representative Director|
|2017||Chief Financial Officer, Executive Officer|
|2018||President - Development, Chief Medical Officer|
|2017||Chief Administrative Officer, Chief Ethics & Compliance Officer, Executive Officer|
- BRIEF- Astellas Pharma signs exclusive licensing agreement with Aquinox Pharmaceuticals
- BRIEF-Aquinox And Astellas Announce Exclusive Licensing Agreement For Rosiptor In Asia-Pacific Region Including Japan
- BRIEF-FDA Approves Supplemental New Drug Application For Myrbetriq For Treatment Of Overactive Bladder Symptoms
- BRIEF-Astellas Pharma to retire treasury shares
- BRIEF-Astellas Says To Cancel Treasury Stock Equivalent To 4.3 Percent Of Shares Outstanding